SciBase Secures Payer Coverage with Highmark for Nevisense

STOCKHOLM, October 14, 2026 /CourierPR/ -- SciBase Holding AB, a global medical technology company specializing in early detection and prevention in dermatology, has made a significant stride in its U.S. commercialization strategy. The company's Nevisense technology has received its first positive medical policy from Highmark Blue Cross Blue Shield, one of the largest Blue Cross Blue Shield organizations in the United States. This decision marks a major milestone in SciBase's U.S. commercialization strategy and changes the reimbursement landscape for Nevisense.

The policy covers the use of Nevisense when a dermatologist is evaluating a clinically atypical suspicious pigmented lesion and is considering a biopsy. The procedure is reported with CPT code 0658T, and the key criteria include: - Melanoma is part of the differential diagnosis - The lesion is on the trunk or extremities and measures 2 mm to 20 mm - The patient is 18 or older - The lesion is not on a mucosal surface, palm, sole, or nail, and is not ulcerated, bleeding, or recently traumatized - The device is FDA-approved and used by a dermatologist trained in clinical and dermoscopic evaluation of pigmented lesions

Highmark, together with its Blue-branded affiliates, is one of the largest Blue Cross Blue Shield affiliated organizations in the United States, serving over 7 million members across multiple states. This decision represents more than the addition of a new payer. It begins to address one of the principal constraints on U.S. commercial scale and creates a pathway to convert established clinical adoption into broader reimbursed utilization.

The United States is SciBase's largest commercial opportunity. Approximately 6,500 to 7,000 private dermatology clinics operate in the U.S., with around 6,000 considered relevant for Nevisense. An estimated 4 to 4.5 million skin biopsies are performed annually. The Highmark decision is significant as it introduces a new growth driver to an existing business, expanding the number of dermatology practices and patients that can access Nevisense within a reimbursed model.

SciBase will continue its engagement across the U.S. payer market while expanding commercial activity in geographies where reimbursement is available. The company has been listed on the Nasdaq First North Growth Market exchange since June 2, 2015, and the company's Certified Adviser is Carnegie Investment Bank AB (publ).

This information was submitted for publication through the agency of the contact person set out below, at 09:00 AM CEST on October 14, 2026.